Clinical Scorecard: Effectiveness of Combining Gegen Qinlian Decoction with Metformin in Managing Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

At a Glance

Key Highlights

• GQD plus metformin did not significantly reduce HbA1c compared to metformin alone.
• Statistically significant reductions in fasting plasma glucose (FPG) and 2-hour postprandial glucose (2hPG) were observed.
• Substantial heterogeneity and very low certainty of evidence were noted across trials.
• Eight randomized controlled trials involving 725 participants were included in the analysis.
• Larger, well-designed trials are needed to confirm findings.

Guideline-Based Recommendations

Diagnosis

• Diagnosis of Type 2 Diabetes Mellitus in adults.

Management

• Consider GQD as an adjunct to metformin with caution due to low certainty of evidence.

Monitoring & Follow-up

• Monitor glycemic outcomes including HbA1c, FPG, and 2hPG.

Risks

• High risk of bias and inconsistency in included studies.

Patient & Prescribing Data

Adults diagnosed with Type 2 Diabetes Mellitus.

GQD is used as an adjunctive treatment but evidence for its efficacy remains uncertain.

Clinical Best Practices

• Use metformin as the first-line treatment for Type 2 Diabetes Mellitus.
• Evaluate the need for adjunctive therapies based on individual patient glycemic control.

Related Resources & Content

• Cochrane RoB 2 tool
• GRADE framework
• PRISMA 2020 statement